

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/20, 9/16	A1	(11) International Publication Number: WO 98/56357 (43) International Publication Date: 17 December 1998 (17.12.98)
(21) International Application Number: PCT/US97/10705 (22) International Filing Date: 11 June 1997 (11.06.97) (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: BROAD, Neville, W.; 87 Jefferson Road, Sheerness, Kent ME12 2PX (GB). CARMODY, Alan, F.; 90 Gadby Road, Sittingbourne, Kent ME10 1TL (GB). FEELY, Liam, C.; 30 Fielding Drive, Larkfield, Aylesford, Kent ME20 6TY (GB). WITHERS, Brian, C.; 21 Sandy Mount, Bearsted, Maidstone, Kent ME14 4PJ (GB). (74) Agents: ANAND, Mona et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).		(81) Designated States: BG, NO, SI, SK. Published <i>With international search report.</i>
(54) Title: A CONTROLLED RELEASE FORMULATION FOR POORLY SOLUBLE BASIC DRUGS (57) Abstract A controlled release, oral, solid, pharmaceutical composition for a reduced daily dosage regimen is described where the therapeutic ingredient is a poorly soluble basic drug. The formulation comprises the use of a water-soluble alginate salt, a complex salt of alginic acid and an organic carboxylic acid in admixture with the therapeutic drug. A particular embodiment comprising a once a day dosage form for clarithromycin is also described.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A CONTROLLED RELEASE FORMULATION FOR POORLY SOLUBLE BASIC DRUGS

Field of the Invention

This invention relates to a controlled slow release oral dosage form for at least one sparingly soluble basic drug useful to reduce the daily dosage regimen. More particularly, the invention relates to a once daily
5 formulation of clarithromycin.

Background of the Invention

The advent of controlled release dosage forms has provided a benefit to the pharmaceutical industry. Controlled release formulations have
10 allowed the possibility of reducing dosage regimens for drugs, especially those administered orally to outpatients.

The advantages of reduced dosage regimens for the outpatient are convenience and, more importantly, better assurance of compliance. For example, the reduction of a dose regimen from four times a day (q.i.d.) to
15 three times a day (t.i.d.) allows the patient to take the prescribed drug during waking hours. A reduction of a dose regimen to twice a day (b.i.d.) allows the patient to take the prescribed drug in the morning and in the evening, which provides greater convenience; e.g., the patient is not required to carry an additional when away from the home. Of course, the most convenient
20 dosage form is a once daily dose regimen. Unfortunately, the pharmacokinetic properties (e.g., absorption, elimination, and metabolism) of most drugs does not permit them facilely to be prepared in a single oral dosage form and provide controlled efficient release of the drug throughout a 24-hour period with reproducible bioavailability.

25 One method of improving controlled slow release solid preparations has been the development of preparations containing an alginate gel. Typically, a water soluble alginate such as sodium alginate and calcium ions in the form of a calcium salt are reacted to cross-link the alginate converting it into an insoluble calcium alginate gel. On the addition of a strong acid to
30 the mixture of sodium alginate and calcium salt, the calcium salt is slowly ionized to yield calcium ions. The calcium ions then react with the soluble alginate to form an insoluble calcium alginate gel. Gelation proceeds

through gradual ionization of the calcium salt. With these formulations, the controlled release properties of the alginate gel have been varied by varying the molecular weight of alginate, the alginate concentration, the type of polyvalent cation cross-linking agent or the concentration of the cation.

Granted European Patent 188040-B1 and its counterpart, U.S. patent 4,842,866, describe an improved gel-type alginate composition that is slowly soluble in bodily fluids, such as of the gastrointestinal ("GI") tract, containing a therapeutically effective amount of at least one therapeutically active agent that is gradually released as the alginate hydrates, characterized in that there are present in the preparation both a water-soluble alginate, especially sodium alginate, and a complex salt of alginic acid, especially sodium-calcium alginate, having one cation that alone yields a soluble alginate salt and another cation that alone yields an insoluble alginate salt. The disclosure of the U.S. counterpart, U.S. 4,842,866, is incorporated by reference in its entirety.

The use of the technology developed in the above-mentioned patents, however, was not found to be applicable with poorly water soluble drugs. For example, an *in vitro* drug release study from an alginate formulation of clarithromycin was observed to be too slow. Similarly, with erythromycin, *in vivo* animal studies showed that reproducibly bioavailable controlled release formulations were not possible using alginates or any other monolithic hydrogel tablets. It was concluded that macrolides such as erythromycin in a simple monolithic hydrogel tablet will not produce a suitable controlled release dosage form due to the problems of acid instability, poor drug solubility and variable GI transit.

An oral formulation containing 6-O-methylerythromycin A and citric acid with improved bioavailability has been reported in Japanese Kokai 163823/1985, as abstracted in WPI Acc. No. 85-247033/40.

It is an object of the present invention to reduce the daily dose regimen of a poorly water soluble basic drug with a controlled release formulation.

The present invention overcomes the problems of slow release and potentially poor or variable absorption with poorly soluble basic drugs by combining an organic acid and the drug into the alginate formulation.

Summary of the Invention

The present invention provides for reduced daily dosing of poorly soluble basic drugs by applying the alginate matrix with the incorporation of an organic acid. A basic drug's solubility decreases as it proceeds distally towards the large intestine (pH 8.0) while it is soluble in the stomach and the upper or proximal region of the small intestine. Thus, a poorly soluble basic drug will lead to less drug being available for absorption in the lower or distal intestine. The inclusion of the organic acid within the formulation has overcome this problem. While not intending to be bound by any particular theory, it is believed that the formulation with the organic acid creates a microenvironment of low pH to enhance the solubility of the drug within the dosage form as it moves down the GI tract.

Accordingly, the present invention includes a controlled release solid pharmaceutical composition adapted for oral administration comprising:

- a therapeutically effective amount of at least one basic drug having a water solubility of less than 1 part per 30 parts water;
- a water-soluble alginate salt;
- a complex salt of alginic acid, and
- an effective amount of an organic carboxylic acid to facilitate dissolution of the basic drug.

A particular aspect of the present invention is the preparation of a once daily dosage regimen for clarithromycin which currently is administered twice daily as a 250 mg or 500 mg tablet depending on the type of bacterial infection to be treated. The exact site of clarithromycin absorption *in vivo* is uncertain. However, it is known that clarithromycin is very soluble in the stomach (pH 1.2) and fairly soluble in the upper region of the small intestine (pH 5.0) where absorption is most likely to occur. Because the drug's solubility decreases in the lower intestine (pH 6 to 8), this leads to less drug being available for absorption. The present invention provides a way of overcoming this problem by using the alginate formulation with an organic acid, particularly, for example, citric acid.

Accordingly, a second aspect of the present invention is a controlled release, solid pharmaceutical composition adapted for oral administration of a once a day dosage regimen comprising:

- about 500 mg of clarithromycin;
- from about 75 to 400 mg of sodium alginate;

from about 10 to 400 mg of sodium-calcium alginate, and about 128 mg of citric acid.

Detailed Description of the Preferred Embodiment

5 The object of the present invention is to provide a controlled release pharmaceutical composition where a poorly soluble basic drug may be released continually from the dosage form as it proceeds through the GI tract.

10 The present invention thus provides for a once a day daily dose regimen for at least one poorly soluble basic drug by administering a controlled release, solid pharmaceutical composition adapted for oral administration to a patient in need thereof. A preferred composition is in tablet form.

15 A poorly soluble or sparingly water-soluble basic drug is a drug that has a solubility of less than 1 part in 30 parts of water. The present invention may apply also to even less soluble drugs for example up to a solubility of one part in 10,000 parts water.

20 By way of example, sparingly soluble basic drugs may include antibiotics such as, for example, sulfamethoxazole with a solubility of 1 in 3,400 (parts of water); tetracycline, 1 in 2,500; metronidazole and cimetidine (a histamine H₂ receptor antagonist for treating ulcers), both about 1 in 100 to 1 in 1,000; indapamide (an antihypertense/diuretic), 1 in more than 10,000; atenolol (an antihypertensive), about 1 in 30 to 1 in 100; diazepam (tranquilizer), ranging from 1 in 1,000 to 1 in 10,000.

25 As a preferred basic drug, the present invention includes macrolides which are also poorly soluble. Examples of macrolides are erythromycin with a solubility of one part in 1,000 parts of water; dirithromycin, with similar solubility properties as erythromycin; josamycin, midecamycin, kitasamycin, all three being very slightly soluble in water, ranging from
30 about 1 in 1,000 to 1 in 10,000; and tylosin which is used for veterinary purposes only and with a solubility ranging from about 1 in 100 to 1 in 1,000. Other macrolides which may be included are, for example, roxithromycin, rokitamycin, oleandomycin, miocamycin, flurithromycin, rosaramicin, azithromycin, and compounds designated ABT-229 or ABT-269. The most
35 preferred macrolide for the present invention is clarithromycin having a solubility of about one part in 1,000 parts of water.

The pharmaceutical composition of the present invention may include other drugs in combination with a poorly soluble basic drug wherever known combination therapy is required or beneficial.

Thus, for example, with macrolides, erythromycin or clarithromycin
5 may be formulated in combination with a preparation for standard therapy of gastritis, ulcers or gastroesophageal reflux disease (GERD), such as preparations containing anti-ulcer or anti-gastritis medicaments; e.g., selected among gastric secretion inhibiting compounds such as omeprazole, cimetidine, ranitidine, lansoprazole, pantoprazole, sucralfate, famotidine, or
10 nizatidine, or antacids such as magnesium hydroxide, aluminum hydroxide, sodium carbonate, sodium hydrogen carbonate, simethicone or aluminum magnesium hydroxide or hydrate thereof (such as the monohydrate known as magaldrate).

Another macrolide, particularly erythromycin or clarithromycin,
15 pharmaceutical composition of the present invention may be adapted to be administered in combination with a preparation containing bismuth salts such as bismuth subcitrate, bismuth subsalicylate, bismuth subcarbonate, bismuth subnitrate or bismuth subgallate.

The amount of drug or drugs in the pharmaceutical composition
20 may vary from about 40 to 75% of the total composition or tablet. For clarithromycin, the amount may preferably vary over 50% and up to 75% of the weight of the total composition or tablet.

The release rate of the formulation is controlled using a matrix based on a water-soluble alginate salt and a complex salt of alginic acid.

25 While sodium alginate is normally employed in the practice of this invention, the sodium cation may be replaced by another cation; e.g., potassium or other alkaline metal, magnesium, or ammonium to yield a soluble alginate salt. Thus, the alginate could also be, for example, potassium alginate or ammonium alginate.

30 The complex salt of alginic acid is a sodium-calcium complex salt of alginic in which the amount of calcium is precisely controlled, and which is self-gelling without the necessity of reacting with the stomach acid or additional calcium ions. While sodium-calcium alginate is normally employed in the practice of this invention, the sodium cation may be
35 replaced by another cation that yields a soluble alginate salt; e.g., potassium or other alkaline metal, magnesium, or ammonium, and the calcium cation can also be replaced by another polyvalent cation (except for magnesium)

that yields an insoluble alginate salt; e.g., strontium, iron, or barium. The most preferable preparations described herein typically include sodium alginate, for example, that manufactured and sold by Alginate Industries, Ltd., England, under the trademark "Manucol", and sodium-calcium
5 alginate manufactured and sold by Kelco Division of Merck and Co., Inc., San Diego, California, U.S.A., under the trademark "Kelset".

The weight ratio of soluble alginate salt to complex salt of alginic acid may vary from about 16:1 to 1:1, preferably from about 8:1 to 2:1. The same ratio of course applies to the ratio of sodium alginate to sodium-calcium
10 alginate. The combination of soluble alginate and complex salt to form an insoluble salt has been described in the art from European Patent 188040, as mentioned above, to provide controlled release formulations.

The organic acid required in the control release formulation of the present invention is an amount of acid effective to create a micro-
15 environment of low pH, less than 7.0, in the vicinity of the hydrating dosage form. Viewed differently, an effective amount of organic acid is the amount which facilitates dissolution of the basic drug throughout the GI tract. The precise amount may vary depending on the acid used and the choice of basic drug as will be known to one skilled in the art. The ratio is a
20 molar ratio and may vary from about 0.2:1 to 5:1 of acid to drug. Preferably, a molar ratio of 1:1 of acid to drug is used.

The organic acid for purposes of the present invention includes any organic carboxylic acid, preferably an aliphatic organic carboxylic acid having anywhere from C₃-C₂₀ carbon atoms. Preferred are, for example, tartaric
25 acid, malic acid, succinic acid, glutaric acid, glutamic acid, maleic acid, mandelic acid and citric acid. The most preferred acid is citric acid.

A particular and preferred embodiment of the present invention is a controlled release, solid pharmaceutical composition adapted for oral administration of a once a day dosage regimen comprising:

30 about 500 mg of clarithromycin;
from about 75 to 400 mg of sodium alginate;
from about 10 to 400 mg of sodium-calcium alginate, and about 128 mg of citric acid.

Preferably, the composition contains from about 80 to 200 mg of
35 sodium alginate and from about 10 to 40 mg of sodium-calcium alginate. Most preferably, the composition contains about 120 mg of sodium malginate and about 15 mg of sodium calcium alginate.

The composition is also preferably in the form of a tablet but may also be in capsule or pellet/granule form.

Other ingredients usually used in a preparation in accordance with the invention may include pharmaceutically acceptable excipients, such as
5 preservatives, diluents; e.g., starch or microcrystalline cellulose; binders
such as starch, polyvinyl pyrrolidone (povidone) and sodium
carboxymethylcellulose; glidants or lubricants, such as talc and magnesium
stearate; bulking agents such as lactose; and approved coloring agents. The
dosage form may also be coated with materials not specifically designed for
10 control or modification of drug release.

The preparation may be processed into tablets, suppositories or used for filling capsules. The preparation may also be coated when desired, for example, to mask an otherwise bitterly tasting preparation.

By way of example of the present invention, bioavailability studies
15 on a representative formulation of the present invention containing
clarithromycin, 500 mg, was found to meet the acceptance criteria for a
successful once daily dosage formulation. This means that it achieved an
area under the curve AUC_{0-24} at least equivalent to the 250 mg twice a day
(BID) dose regimen, and clarithromycin plasma concentrations at 24 hours
20 were similar to the 250 mg BID dose regimen.

Examples

Example 1: Tablet Manufacturing Details

1a. Granulation of controlled release

All tablet formulations used the following general manufacturing method. The active drug, polymer, binding agent and remaining excipients were screened through a 850 μ m aperture screen to remove any large agglomerates. The screened material was then dry blended using a
30 planetary mixer set at the lowest speed for 5 minutes. The blended material was granulated by adding a 50/50 v/v solution of alcohol and water in small amounts until a suitable granulated mass was obtained. The wet mass was passed through a 4.0 mm aperture screen on to paper lined trays and dried in a hot air oven at 50°C until the granule had a moisture content of less
35 than 4% w/w (determined using Sartorius IR balance. Model: YTC01L. Conditions: 98°C for 15 minutes). Finally, the dried granule was passed

through a 850 μm aperture screen and blended with tablet lubricants for 5 minutes, using a planetary mixer set at the lowest speed.

1b. Compression

5 Tablets were compressed using a rotary tablet machine, fitted with ovaloid punches. Individual formulations A, B, and C were compressed to a tablet crushing strength which produced tablets of suitable thickness and friability. The tablet compositions are given in Table 1.

Table 1

Formulation:	A	B	C
<u>Ingredients</u>	mg/tablet	mg/tablet	mg/tablet
Clarithromycin	500	500	500
Citric Acid Anhydrous USP	128	128	128
Sodium alginate	80	120	180
Sodium calcium alginate	10	15	22.5
Lactose 300 mesh	100	100	100
Povidone K (29-32)	30	30	30
Talc, purified, powder	30	30	30
Stearic acid	21	21	21
Magnesium stearate	10	10	10

Example 2: Bioavailability Study

15 2a. Materials and Supplies

A study compared the plasma concentration profiles of the three 500 mg once-daily (QD) formulations A, B, and C, above, with a twice daily dosing regimen of the commercially available 250 mg BIAXIN® tablet as a control (i.e. 250 mg BID, herein referred to Formulation D) at steady state.

20 The acceptance criteria for a successful QD formulation were:

- AUC₀₋₂₄ at least equivalent to the 250 mg twice a day (BID) dosing regimen.
- Clarithromycin plasma concentrations at 24 hours equivalent to the 250 mg BID dosing regimen.

2b. Study Design and Results

The study was conducted as a Phase I, multi dose, open, randomised, four-period, balanced crossover study. Suitable patients were screened with a complete history, physical examination and laboratory profile, including assessment of hematological, renal, and liver parameters.

Eight healthy male volunteers between 18-50 years of age were dosed on the morning of days 1, 2 and 3 in each of the four study periods. Formulation D (BIAXIN® clarithromycin 250 mg) was also dosed on the evening on days 1, 2, and 3 in each of the study periods. Each subject received all formulations upon study completion.

Blood samples were collected prior to dosing on day 3 (0 hour) and at 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing. All samples were transferred to heparinised collection tubes and centrifuged. The separated plasma was split into equal volumes and transferred into appropriately labelled tubes and frozen immediately. The plasma samples were kept frozen until assayed.

Plasma samples were assayed using the large plate bioassay. This method measured total antibiotic activity, and expresses the results in terms of clarithromycin, mcg/ml.

2c. Data and Statistical Analysis

The bioequivalence of the three once daily formulations with the standard tablet was assessed by a two, one-sided t-test procedure. The 90% confidence intervals were calculated from analysis of the natural logarithms of AUC, C_{\max} and concentration at 24 hours. These were obtained by exponentiating the endpoints of the 90% confidence intervals for the difference in mean logarithms. Bioequivalence between formulations is inferred if these limits lay within the range of 0.80 to 1.25. In addition, 90% confidence intervals for the ratios of means were obtained from analysis of untransformed AUC and concentration at 24 hours. The results of this analysis are summarized in Tables 3, 4, and 5. The pharmacokinetic data are shown in Table 2.

-10-

Table 2: Pharmacokinetic Data

Parameter	Formula D (250 mg BID)	Formula A	Formula B	Formula C
AUC ₀₋₂₄ mcg.h/ml (range)	32.16* (25.66-42.70)	31.44 (21.16-38.50)	32.32 (24.65-40.78)	28.69 (24.61-32.74)
C _{max} mcg/ml (range)	2.28 (1.49-3.34)	2.42 (1.53-3.26)	2.41 (1.81-3.07)	2.00 (1.62-2.40)
T _{max} Hours (range)	2 (1-4)	6 (3-8)	6 (3-8)	6 (4-10)
Concentration mcg/ml at 24 hr (range)	0.72 (0.53-1.05)	0.57 (0.33-0.91)	0.65 (0.30-0.87)	0.66 (0.37-0.91)

*As the plasma sampling program did not fully monitor the second standard tablet, AUC₀₋₂₄ value was calculated by multiplying the AUC₀₋₁₂ value by 2.

5

Table 3: Results of Statistical Analysis
AUC

Formula	AUC ₀₋₂₄ mcg.h/ml	Relative Bioavailability (90% confidence intervals)	
		Untransformed data	Ln transformed data
A	31.44	0.98 (0.86-1.10)	0.98 (0.84-1.14)
B	32.32	1.01 (0.88-1.14)	1.01 (0.88-1.16)
C	28.69	0.89 (0.80-0.98)	0.90 (0.80-1.02)

10

Table 4: Results of Statistical Analysis
C_{max}

Formula	C _{max} mcg/ml	Relative Bioavailability (90% confidence intervals)	
		Untransformed data	Ln transformed data
A	2.42	1.06 (0.86-1.26)	1.07 (0.87-1.32)
B	2.41	1.06 (0.86-1.26)	1.08 (0.90-1.31)
C	2.00	0.88 (0.75-1.01)	0.90 (0.76-1.06)

15

Table 5: Results of Statistical Analysis
Concentration at 24 Hours

Formula	C _{max} mcg/ml	Relative Bioavailability (90% confidence intervals)	
		Untransformed data	Ln transformed data
A	0.57	0.79 (0.62-0.99)	0.79 (0.63-0.99)
B	0.65	0.90 (0.79-1.01)	0.89 (0.68-1.15)
C	0.66	0.92 (0.76-1.08)	0.90 (0.71-1.15)

5

2d. Discussion

The mean AUC ratio, at 90% confidence limits, show that Formulations A, B and C are bioequivalent with the standard dosing regimen. All three formulations showed therapeutic levels at C₂₄ hours.

10 C_{max} limits (untransformed) are acceptable for most formulations. All three once daily formulations demonstrate extended absorption of clarithromycin when compared with the standard formulation.

15 Formulations A and B, despite containing different quantities of alginates, produced similar *in vivo* profiles. However, previous studies have shown that reproducibility of release profiles is improved by increasing the quantity of alginate. Therefore formulation B showed best overall results.

20 The above specification, examples and data provide a complete description of the manufacture and use of the composition of the invention. Since many embodiments of the invention can be made without departing from the spirit and scope of the invention, the invention resides in the claims hereinafter appended.

WE CLAIM:

- 1 1. A controlled release, solid pharmaceutical composition adapted
2 for oral administration comprising:
3 a therapeutically effective amount of at least one basic drug having a
4 water solubility of less than 1 part per 30 parts water;
5 a water-soluble alginate salt;
6 a complex salt of alginic acid, and
7 an effective amount of an organic carboxylic acid to facilitate
8 dissolution of the basic drug.
2. The composition of claim 1, in tablet form.
3. The composition of claim 1, in the form of a once a day dosage regimen.
4. The composition of claim 1, wherein the basic drug is a macrolide.
5. The composition of claim 4, wherein the macrolide is clarithromycin.
6. The composition of claim 1, wherein the water-soluble alginate salt is sodium alginate.
7. The composition of claim 1, wherein the complex salt of alginic acid is sodium-calcium alginate.
8. The composition of claim 1, wherein the organic carboxylic acid is selected from the group consisting of tartaric, malic, succinic, glutaric, glutamic, maleic, mandelic and citric acid.
9. The composition of claim 8, wherein the organic carboxylic acid is citric acid.
10. The composition of claim 1, wherein the weight ratio of soluble alginate salt to complex salt of alginic acid is about 16:1 to 1:1.
11. The composition of claim 10, wherein the weight ratio of sodium alginate to sodium-calcium alginate is about 16:1 to 1:1.
12. The composition of claim 11, wherein the weight ratio of sodium alginate to sodium-calcium alginate is about 8:1 to 2:1.

-13-

13. The composition of claim 1, wherein the molar ratio of organic acid to basic drug is about 0.2:1 to 5:1.

14. The composition of claim 1, wherein the molar ratio of organic acid to basic drug is about 1:1.

15. The composition of claim 1, wherein the basic drug is selected from the group consisting of sulfamethoxazole, metronidazole, cimetidine, indapamide, atenolol and diazepam.

16. The composition of claim 4, wherein the macrolide is selected from the group consisting of erythromycin, dirithromycin, azithromycin, roxithromycin and ABT-229.

17. A controlled release, solid pharmaceutical composition adapted for oral administration of a once a day dosage regimen comprising:
about 500 mg of clarithromycin;
from about 75 to 400 mg of sodium-calcium alginate, and about 128 mg of citric acid.

18. The composition of claim 17 comprising:
from about 80 to 200 mg of sodium alginate, and
from about 10 to 40 mg of sodium-calcium alginate.

19. The composition of claim 18 comprising:
about 120 mg of sodium alginate, and
about 15 mg of sodium-calcium alginate.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/10705

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/20 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE WPI Week 8540 Derwent Publications Ltd., London, GB; AN 85-247033 '40! XP002028797 cited in the application see abstract & JP 60 163 823 A (TAISHO PHARMACEUT. KK) 26 August 1985 ---	1-19
A	EP 0 188 040 A (ABBOTT) 23 July 1986 cited in the application see the whole document ---	1-19
E	WO 97 22335 A (ABBOTT) 26 June 1997 see the whole document -----	1-19

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 February 1998

Date of mailing of the international search report

18/02/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/10705

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 188040 A	23-07-86	CA 1273873 A	11-09-90
		US 4842866 A	27-06-89
WO 9722335 A	26-06-97	US 5705190 A	06-01-98
		AU 1025297 A	14-07-97
		CA 2209714 A	26-06-97
		CZ 9702212 A	17-12-97
		EP 0799028 A	08-10-97
		PL 321363 A	08-12-97

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspt